News & Events

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Pricing of Initial Public Offering

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma

IO Biotech Announces First Patient Dosed in Phase 2 Trial in Head and Neck Cancer Conducted in a Collaboration with Cliniques Universitaires Saint-Luc in Belgium

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent

Exciting preclinical data confirm T-win MOA: IDO1 vaccine modulates tumor microenvironment leading to tumor reduction

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

IO Biotech to Participate in Panel Discussion at 30th Annual Cancer Progress Conference in New York

IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019

IO Biotech to participate in panel discussion at Biotech Showcase in San Francisco on January 7th

New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

New article published: “The T-win® technology: immune-modulating vaccines“

IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

Pre-clinical data to be presented at the AACR Annual Meeting 2018

New article published: “Immunoregulatory antigens – novel targets for cancer immunotherapy“

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

IO Biotech to participate in panel discussion at BIO-Europe Spring in Amsterdam on March 12, 2018

New article published in Cancer Research: “The Balance Players of the Adaptive Immune System“

IO Biotech presented posters on preclinical studies at SITC Annual Meeting

Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress

IO Biotech appoints Dr. Eva Ehrnrooth as Chief Medical Officer

SMi conference speech on targeting the tumor microenvironment

Poster on planned phase II study at ASCO

IO Biotech closes Series A Round including new investor Sunstone Capital to the investor syndicate

The immune system strikes back

IO Biotech appoints Dr Peter Hirth as Chairman of the Board

Positive results from Immunoscore® study presented at ASCO 2016

Innovation Fund Denmark grants Industrial PhD Project

IO Biotech invited to speak at BioEquity Europe 2016

IO Biotech raises 11 Million Euro in a Series A Financing Round

IO Biotech CSO speaks at Cancer Biotherapeutics Conference

IO Biotech receives InnoBooster grant

IO Biotech CEO a panelist at Cancer Progress Conference